CLARAMETYX BIOSCIENCES
Clarametyx Biosciences is a late preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms.
CLARAMETYX BIOSCIENCES
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2020-01-01
Address:
Columbus, Ohio, United States
Country:
United States
Website Url:
http://www.clarametyx.com
Total Employee:
1+
Status:
Active
Contact:
614.686.2689
Email Addresses:
[email protected]
Total Funding:
21.24 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Neumora Therapeutics
Neumora Therapeutics operates as a clinical-stage biotechnology company.
Current Advisors List
Current Employees Featured
Founder
Investors List
CARB-X
CARB-X investment in Grant - Clarametyx Biosciences
National Institute of Deafness & Communications Disorders (NIDCD)
National Institute of Deafness & Communications Disorders (NIDCD) investment in Grant - Clarametyx Biosciences
CARB-X
CARB-X investment in Grant - Clarametyx Biosciences
Official Site Inspections
http://www.clarametyx.com Semrush global rank: 5.84 M Semrush visits lastest month: 1.42 K
- Host name: 77.71.72.148.host.secureserver.net
- IP address: 148.72.71.77
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Clarametyx Biosciences" on Search Engine
Get To Know Us - Clarametyx Biosciences
Guided by the discoverers and inventors of this novel approach as well as expert entrepreneurial leaders, we rigorously pursue our mission to deliver a powerful new tool …See details»
Clarametyx Biosciences | LinkedIn
Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel …See details»
Clarametyx Biosciences Announces $33 Million Series A …
COLUMBUS, Ohio – January 5, 2024 – Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical stage company developing targeted, immune-enabling biologic therapies to …See details»
Clarametyx Biosciences Awarded $3.15 Million Grant From NIH …
Dec 20, 2021 Clarametyx received an NIH grant for up to $3.15 million over 3 years to accelerate development of a novel, broad spectrum vaccine for otitis media.See details»
Clarametyx Biosciences Announces $33M Series A Financing to …
Jan 5, 2024 Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the …See details»
Clarametyx Biosciences - Crunchbase Company Profile & Funding
Phone Number 614.686.2689. Clarametyx Biosciences is a late preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to …See details»
Clarametyx Biosciences Company Profile 2024: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for Clarametyx Biosciences. Use the PitchBook Platform to explore the full profile.See details»
News & Updates - Clarametyx Biosciences
May 28, 2024 Clarametyx Biosciences Announces Changes to Its Scientific Advisory Board. Read More. November 30, 2022. Clarametyx Initiates Phase 1 Study of Immune …See details»
Clarametyx Biosciences Expands Team Expertise to Accelerate …
Apr 22, 2024 Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the …See details»
Clarametyx Biosciences | Rev1 Ventures
Clarametyx Biosciences is a preclinical biotechnology company developing a novel, non-antibiotic therapeutic and vaccine platform to treat and prevent bacterial biofilm …See details»
Clarametyx Biosciences | VentureRadar
The Clarametyx platform is designed to precisely remove a universal, pathogen-agnostic target within this matrix, rapidly and effectively collapsing the protective shield and …See details»
Clarametyx Biosciences Launches With an Ambitious Strategy to …
May 4, 2020 Focused initially on respiratory tract infections, Clarametyx will exploit the paradigm-shifting platform technology to develop a pipeline of high-value therapeutic …See details»
CARB-X is funding Clarametyx Biosciences to develop an …
Nov 18, 2020 Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the …See details»
Clarametyx Initiates Phase 1 Study of Immune-enabling Antibody …
Nov 30, 2022 Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting …See details»
Our Platform - Clarametyx Biosciences
CMTX-301 employs Clarametyx’ anti-DNABII technology through a vaccination approach in at-risk populations. This approach prevents the development of bacterial biofilm, …See details»
Clarametyx Biosciences Appoints Renowned Experts to Augment …
May 28, 2024 Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting …See details»
Clarametyx Biosciences - Contacts, Employees, Board Members, …
Clarametyx Biosciences has 4 current employee profiles, including Co-Founder Co-Chair Peter Kleinhenz. Clarametyx Biosciences has 2 board members and advisors, …See details»
Our Science - Clarametyx Biosciences
Slime-like, protected communities of bacteria that shield bacteria from immune or antibiotic attack. Composed of extracellular polymeric substance (EPS) and a scaffolding matrix of …See details»
Clarametyx Biosciences - Funding, Financials, Valuation & Investors
Their latest funding was raised on Jan 5, 2024 from a Series A round. Clarametyx Biosciences is funded by 9 investors. Nationwide Children's Hospital and Ohio …See details»
Clarametyx Biosciences Launches with an Ambitious Strategy to …
May 4, 2020 Clarametyx Biosciences is combating the formidable challenge of persistent antibiotic-resistant infections through an innovative technology platform that targets the …See details»